57 citations
,
March 2011 in “The American Journal of Dermatopathology”
This study found that permanent alopecia can occur after certain chemotherapy treatments and presents as nonscarring hair loss similar to androgenetic alopecia, with specific histological features that could be misdiagnosed without proper clinicopathological correlation.
39 citations
,
May 2019 in “Journal of the American Academy of Dermatology”
This study found that nonscarring alopecia in patients with systemic lupus erythematosus may indicate higher disease activity, as evidenced by specific histological and immunofluorescence changes.
A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.
Topical tacrolimus is being considered for androgenetic alopecia, though its effectiveness is unproven. Other treatments mentioned include minoxidil, dutasteride, cyclosporine, and teicoplanin, with discussions on blocking the prolactin receptor for hair growth.
Oral dutasteride 0.5 mg combined with oral minoxidil 2.5 mg is highly effective for male androgenetic alopecia, showing over 60% improvement and 98% stabilization at 6 months, with low adverse event rates. Patients with severe baseline conditions respond better and faster to this treatment.
L. reuteri, a probiotic, is being explored for its potential benefits in treating androgenic alopecia, possibly enhancing finasteride's effects and reducing inflammation. The user combines this with finasteride, oral minoxidil, and other supplements, noting some improvement in hair loss.
Hair loss treatments that avoid significantly lowering systemic DHT levels, focusing on topical options like dutasteride mesotherapy, minoxidil, and ketoconazole. The user is exploring alternatives like KX-826 and RU58841 due to concerns about hormone levels.
How does topical Estradiol compare to oral Estradiol in treating alopecia?Topical estradiol delivers hormone to the scalp with less systemic exposure, but evidence is thin and it is still a hormone. It needs a doctor's supervision, and people with estrogen-sensitive cancers must not use it without medical approval.